Page 96 of 100 FirstFirst ... 468687888990919293949596979899100 LastLast
Results 951 to 960 of 992

Thread: Spinal Cord Injury Articles Posted by Manouli

  1. #951
    GEN News Highlights
    More ?
    February 27, 2018
    Human Neural Stem Cells Repair Spinal Cord Injury in Primates


    Surgeons and neuroscientists in the U.S. have successfully grafted human neural progenitor cells (NPCs) into rhesus monkeys with spinal cord injuries (SCIs). The grafts sent out hundreds of thousands of new human axons across the damaged tissue to connect with functional neuronal circuits in the animals’ spinal cords, resulting in improved limb function. The work, headed by a team at the University of California, San Diego (UCSD), represents a significant bridge between earlier work in rodents, and the potential to use similar procedures in humans.
    more...

    https://www.genengnews.com/gen-news-...mates/81255530

  2. #952
    BrainQ aims to cure stroke and spinal cord injuries through mind-reader tech
    Posted 20 hours ago by Sarah Buhr (@sarahbuhr)


    It’s not clear yet what Musk’s startup intends to do with the computer chips it plans to put in our heads, but Johnson’s startup says it is focused on developing “technologies to understand and treat neurological diseases in new and exciting ways.”
    Whatever sector each company goes for, both plan to insert chips in our brains to connect us to computers — the consequences of which could have dramatic effects on human memory, intelligence, communication and many other areas that could rocket humanity forward, should they work out.
    more...

    https://techcrunch.com/2018/02/27/br...d-reader-tech/

  3. #953
    Published on Feb 28, 2018
    Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury
    - Results to Date Show AST-OPC1’s Favorable Safety Profile, Potential for Cell Engraftment and Improved Motor Function -
    - Multiple Additional Data Readouts from SCiStar Study Expected in 2018 into First Quarter of 2019 -
    - Conference Call and Webcast Today, February 28, at 5:00 p.m. ET –
    FREMONT, Calif., Feb. 28, 2018 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today provided additional data from the company’s ongoing Phase 1/2a SCiStar study designed to evaluate the safety and potential efficacy of AST-OPC1 in the treatment of severe cervical spinal cord injury.
    The SCiStar study is an open-label, single-arm trial testing three sequential escalating doses of AST-OPC1 administered at up to 20 million AST-OPC1 cells in 25 subjects with subacute motor complete (AIS-A or AIS-B) cervical (C-4 to C-7) spinal cord injury. These individuals have essentially lost all movement below their injury site and experience severe paralysis of the upper and lower limbs. The SCiStar study consists of five cohorts:
    Cohort Injury Type; AST-OPC1 Dose # of Subjects
    Cohort 1 AIS-A; 2M AST-OPC1 cells
    (low dose for safety evaluation) 3
    Cohort 2 AIS-A; 10M AST-OPC1 cells 6
    Cohort 3 AIS-A; 20M AST-OPC1 cells* 6
    Cohort 4 AIS-B; 10M AST-OPC1 cells 6
    Cohort 5 AIS-B; 20M AST-OPC1 cells* 4
    Total

    more....
    http://asteriasbiotherapeutics.com/i...ases_text.php?

  4. #954
    Revolutionary Robotic Treatment For Patients With Spinal Cord Injuries Now Available In United States
    New advanced technology available at Brooks Rehabilitation, in partnership with Japan-based Cyberdyne, Inc.

    News provided by
    Brooks Rehabilitation
    07:07 ET

    JACKSONVILLE, Fla., March 2, 2018 /PRNewswire/ -- Brooks Rehabilitation, an industry leader in post-acute physical rehabilitation, announced today its partnership with Japanese medical and social innovation company, CYBERDYNE, INC., to introduce and make available the world's first advanced robotic treatment device that has been shown to improve a patient's ability to walk. Individuals with spinal cord injuries can now access FDA-cleared HAL, which is short for Hybrid Assistive Limb, at the Brooks Cybernic* Treatment Center in Jacksonville, FL. The Treatment Center is currently the only facility in the U.S. offering this innovative treatment.
    more...
    https://www.prnewswire.com/news-rele...300607244.html

  5. #955
    Central Minn. woman first patient in clinical trial to help people with spinal cord injuries
    By Nancy Vogt on Mar 8, 2018 at 1:33 p.m.

    CROSSLAKE, Minn.—Since a sleepwalking accident 11 years ago at her Crosslake home, Kathy Allen has lived life paralyzed from the waist down. But she never gave up hope that her condition would improve one day.
    After all those years, Allen recently shared groundbreaking results as the first patient in the E-STAND (Epidural Stimulation After Neurologic Damage) clinical trial.
    "This last year's been way more hope than I've had in probably five years," Allen said at the first Minnesota Spinal Cord & Traumatic Brain Injury Research Symposium held Jan. 31 at Regions Hospital NeuroScience Center in St. Paul, where she talked about her participation in the E-STAND clinical trial. A video of her speech is available on YouTube.
    The trial uses epidural stimulation to restore function and movement for people with spinal cord injuries. The study was set up to ask: Does epidural stimulation have an effect on patients, and does it restore autonomic function?
    Allen had surgery at the end of September, during which a nerve stimulator was placed on her spinal cord and a battery pack was implanted on her left hip. After a month of recovery, Allen turned on the stimulator. She said it felt like a corset, with muscles working the abdomen.
    About a month before the symposium, doctors saw success where "everyone was in awe," Allen said.
    "We turned it on the default setting and both my big toes moved, and that is something that hasn't happened in 11 years," she said. "So it was a rather emotional time. We're hoping that big toes lead to feet, legs and knees. We'll see."



    https://www.duluthnewstribune.com/li...le-spinal-cord

  6. #956
    Research reveals neuroprotective mechanisms of gene and cell medications for spinal cord injuries
    Download PDF Copy
    March 8, 2018
    A joint paper with Kazan State Medical University appeared in Stem Cells International.
    The research was based at the Gene and Cell Technologies Lab of Kazan University.
    Previously, KFU employees suggested using gene and cell therapy to treat spinal injuries. To that end, therapeutic genes were transported to an affected spinal cord area by mononuclear cells of umbilical cord blood. Group Head Yana Mukhamedshina explains that the approach is based on genetic modification of umbilical cord blood cells aimed at increasing their regenerative potential. "In particular, VEGF and GDNF genes, which possess strong neuroprotective and neurotrophic properties, were used continue......
    https://www.news-medical.net/news/20...-injuries.aspx

  7. #957
    Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury
    By GlobeNewswire, March 13, 2018, 07:00:00 AM EDT
    - NSI-566 shown to have restorative function in primate paralysis model -
    - NSI-566 transplantation resulted in measurable improvement in forelimb function -
    GERMANTOWN, Md., March 13, 2018 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq:CUR), a biopharmaceutical company focused on developing novel treatments for nervous system diseases, highlighted the publication of a manuscript in Nature Medicine showing that NSI-566, Neuralstem's lead cell therapy candidate, provided meaningful improvement in forelimb function in a non-human primate model of acute spinal cord injury. The full manuscript can be found here.
    The manuscript, entitled ‘Restorative Effects of Human Neural Stem Cell Grafts on the Primate Spinal Cord,' involved a study to evaluate the potential benefits of transplanting NSI-566 into rhesus monkeys two weeks after they received a hemisection lesion of the cervical spinal cord.
    read...
    https://www.nasdaq.com/press-release...20180313-00307

  8. #958
    Science News
    from research organizations

    Recovery from spinal cord injuries can be predicted
    Date:
    March 7, 2018
    Source:
    University of Zurich
    Summary:
    Injuries to the spinal cord result in tissue loss in the spinal cord and brain. These neurodegenerative changes can be analyzed in detail using neuroimaging methods. Researchers have now for the first time been able to reliably predict the extent of functional recovery in patients suffering from a spinal cord injury two years after a trauma based on the extent and progression of neurodegenerative changes within the first six months after injury.
    read...
    https://www.sciencedaily.com/release...0307161400.htm

  9. #959
    BioArctic Receives Patent Protection in Japan for a Medical Device for Treatment of Patients With Complete Spinal Cord Injury

    News provided by
    BioArctic
    Mar 19, 2018, 08:21 ET
    Share this article
    STOCKHOLM, March 19, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the Japanese Patent Office (JPO) issued a notification to grant the company's patent application in Japan, 2014-545410, for a medical device, which is one of the main components in the product candidate SC0806. The product candidate is a combination of a medical device (implant) and a medicinal product (FGF1) for patients with Complete Spinal Cord Injury. The notification states that the Japanese patent (derived from 2014-545410) will enter into force no later than April 13, 2018.
    continue...
    https://www.prnewswire.com/news-rele...300615829.html

  10. #960
    BioArctic Receives Regulatory Approval in Norway for a Clinical Study in Patients With Complete Spinal Cord Injury
    ⦁ Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact ⦁ pressreleases@franklyinc.com
    SOURCE BioArctic
    STOCKHOLM, March 21, 2018 /PRNewswire/ -- BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the company has received approval by the Norwegian Medicines Agency (NOMA) departments for medicinal products and medical device and the local ethics committee for inclusion of Norwegian patients in BioArctic's ongoing clinical Phase 1/2 study with SC0806. The candidate product is a combination of a medical device (implant) and a medicinal product (FGF1) for patients with complete spinal cord injury.
    read...
    receives-regulatory-approval-in-norway-for-a-clinical-study-in-patients-with-complete-spinal-cord-injury

Similar Threads

  1. Replies: 0
    Last Post: 08-14-2005, 09:16 AM
  2. New articles posted to Research Forums.
    By Wise Young in forum Cure
    Replies: 1
    Last Post: 04-15-2004, 11:41 AM
  3. Replies: 0
    Last Post: 01-14-2004, 12:00 PM
  4. Replies: 8
    Last Post: 05-15-2003, 02:05 AM
  5. Replies: 1
    Last Post: 05-12-2002, 04:07 PM

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •